Alzheimer’s Disability Japan

Eisai Files for Approval of New Alzheimer’s Drug in Japan

Eisai Co said Monday that it has applied for marketing authorization from Japan's Pharmaceuticals and Medical Devices Agency for a new Alzheimer's drug jointly developed with U.S. pharmaceutical company Biogen Inc.

From Jiji

January 16 2023

TOKYO – Eisai Co said Monday that it has applied for marketing authorization from Japan’s Pharmaceuticals and Medical Devices Agency for a new Alzheimer’s drug jointly developed with U.S. pharmaceutical company Biogen Inc.

Before submitting the application, the Japanese drugmaker utilized the PMDA’s prior assessment consultation system to shorten the review period for the drug, lecanemab. The company aims to obtain marketing authorization by the end of this year.

0 comments on “Eisai Files for Approval of New Alzheimer’s Drug in Japan

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: